CIQ

CIQ is a selective positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors containing the GluN2C or GluN2D subunits. It acts by increasing the channel open probability and enhancing the potency of agonists like glutamate and glycine. CIQ is widely utilized as a pharmacological research tool to investigate the functional roles of these specific NMDA receptor subtypes in the central nervous system. In experimental models of Parkinson's disease, CIQ has been used to study the impact of GluN2D activation on dopaminergic neuron survival, where its administration typically contrasts with the neuroprotective effects observed with GluN2D inhibitors. It is not currently in clinical development for human use.

Other names

(S)-Ethyl 2-(4-chlorophenyl)-4-hydroxy-1-(2-(4-benzylpiperazin-1-yl)-2-oxoethyl)-1,2-dihydroquinoline-3-carboxylateCIQ-1CIQ1CIQ 1